MaxLinear's stock fell after earnings, but the analyst maintains a Strong Buy rating with a revised price target of $111 per share, down from $196.50. The drop is attributed to valuation compression and broader semiconductor industry trends rather than a decline in the company's AI connectivity prospects. The analyst keeps the 2028 non-GAAP EPS estimate at $2.78 and applies a forward P/E multiple of 40x, suggesting a 56% upside from current prices. The stock appears undervalued relative to its expected earnings growth, supporting the positive outlook despite near-term challenges like dilution and operating expenses.
The global pharmaceutical surfactants market, valued at $4.5 billion in 2025, is projected to grow to $6.93 billion by 2035 at a CAGR of 4.42%. Growth is fueled by increasing use in drug formulation to enhance solubility, stability, and bioavailabili...
The Dolphin Company's current management proposed selling its main assets in Mexico to Delphinus Blue Planet, a Grupo Xcaret subsidiary, for $20 million. This deal would give Delphinus control over more than 90% of dolphin habitats in Mexico, creatin...
Johnson & Johnson has reached a historic $5.5 billion settlement to resolve claims from about 70,000 women and families alleging its talc products, including Johnson's Baby Powder, contained asbestos and caused cancers such as ovarian cancer and meso...
Bitcoin fell about 2.7% to around $63,200 following the U.S. market close, dragged down by a sharp 10% drop in South Korea's Kospi index, which hit its lowest since April. The U.S. Senate postponed a vote on the CLARITY Act, delaying crypto regulator...
AI coding startup Cursor has introduced Cursor Start, a ₹649 ($7) monthly subscription tailored for India, priced below its $20 Pro plan. India is Cursor's third-largest market with rapid user growth, making it a strategic focus for expansion. The pl...
